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Abstract
Background: Blood-brain barrier (BBB) dysfunction/disruption followed by leukocyte infiltration into the brain
causes neuroinflammation and contributes to morbidity in multiple sclerosis, encephalitis, traumatic brain injury,
and stroke. The identification of pathways that decreases the inflammatory potential of leukocytes would prevent
such injury. Poly(ADP-ribose) polymerase 1 (PARP) controls various genes via its interaction with myriad
transcription factors. Selective PARP inhibitors have appeared lately as potent anti-inflammatory tools. Their effects
are outside the recognized PARP functions in DNA repair and transcriptional regulation. In this study, we explored
the idea that selective inhibition of PARP in leukocytes would diminish their engagement of the brain endothelium.
Methods: Cerebral vascular changes and leukocyte-endothelium interactions were surveyed by intravital
videomicroscopy utilizing a novel in vivo model of localized aseptic meningitis when TNFα was introduced
intracerebrally in wild-type (PARP+/+) and PARP-deficient (PARP−/−) mice. The effects of selective PARP inhibition on
primary human monocytes ability to adhere to or migrate across the BBB were also tested in vitro, employing
primary human brain microvascular endothelial cells (BMVEC) as an in vitro model of the BBB.
Results: PARP suppression in monocytes diminished their adhesion to and migration across BBB in vitro models
and prevented barrier injury. In monocytes, PARP inactivation decreased conformational activation of integrins that
plays a key role in their tissue infiltration. Such changes were mediated by suppression of activation of small Rho
GTPases and cytoskeletal rearrangements in monocytes. In vitro observations were confirmed in vivo showing
diminished leukocyte-endothelial interaction after selective PARP suppression in leukocytes accompanied by BBB
protection. PARP knockout animals demonstrated a substantial diminution of inflammatory responses in brain
microvasculature and a decrease in BBB permeability.
Conclusions: These results suggest PARP inhibition in leukocytes as a novel approach to BBB protection in the
setting of endothelial dysfunction caused by inflammation-induced leukocyte engagement.
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Background
Leukocyte adhesion and migration are mediated by
integrins, adhesion receptors expressed on diverse cell
types participating in cell-to-cell interactions [1–4].
Integrins facilitate bi-directional signaling. Outside-in
transmission involves integrin ligation resulting in
stimulation of several signaling pathways. Ligation of
other receptors can lead to transmission of an inside-out
signal towards the integrin [5]. This signaling usually re-
sults in integrin’s conformational modifications (bend-
ing/unbending) leading to a rapid rise or decline in
integrin-ligand binding affinity and changes in integrin
lateral mobility, which directly regulate cell adhesion po-
tential [4, 6] and is critical for immune system responses
[6]. Most circulating leukocytes display a non-adhesive
phenotype, having integrins in a resting/inactive state.
Leukocytes may roll on endothelial cells, arrest, firmly
adhere, and transmigrate across the endothelial barrier.
In this study, we focused on two major leukocyte integ-
rins [CD49d/CD29, very late antigen-4 (VLA-4), alpha4
beta1 integrin], and [CD11a/CD18, lymphocyte
function-associated antigen-1 (LFA-1), alpha L beta2 in-
tegrin]. VLA-4 and LFA-1 directly mediate cell arrest
under flow conditions, where firm adhesion is mediated
by activated (high-affinity, unbent) integrins. The activa-
tion of integrins, adhesion and migration processes in-
volve a chain of actin cytoskeleton rearrangements and
activation of small Rho GTPases [6–9].
In the search for anti-inflammatory/neuroprotective
compounds, we focused on poly(ADP-ribose) polymerase-
1 (PARP) inhibitors (further referred to as PARPi) that are
currently used in the treatment of cancer [10]. PARP is re-
sponsible for synthesis and transfer of ADP-ribose poly-
mers to target proteins, regulation of DNA repair, and
genomic integrity maintenance [11]. PARP hyperactivity
has been found in a number of central nervous system
(CNS) disorders (including ischemia, neurodegeneration,
and neuroinflammation) [12]. PARP inhibition in macro-
phages/microglia diminished production of inflammatory
mediators [11], decreased the number of T cell subsets,
while increasing the amount of anti-inflammatory cyto-
kines and regulatory, suppressive T lymphocytes [13]. The
first PARPi were discovered in 1980 [14, 15]. All known
PARPis are nicotinamide mimetics that bind in the NAD+
binding pocket of the catalytic domain, with the exception
of indole and coumarin derivatives that bind in the zinc-
finger domains in PARP [14–16]. In the current study, we
used PARPis belonging to the nicotinamide mimetic
group; two of them (olaparib and talazoparib) are cur-
rently in clinical trials for treatment of several malignan-
cies (phase II and III), offering rapid translation to therapy
of immune/inflammatory disorders [10]. PARPi have been
shown to be anti-inflammatory and tissue-protective in
animal models of traumatic brain injury (TBI) [17],
multiple sclerosis (MS) [18], meningitis [19], arthritis [20],
and lung, liver, and kidney injury [21].
Inflammation plays a significant role in neuronal dys-
function and neurocognitive impairment [22]. Neuroin-
flammatory responses are characterized by activation of
resident macrophages and microglia that release cyto-
kines, chemokines, and proteolytic enzymes negatively
affecting neural cells. Inflammatory molecules can
stimulate the brain endothelium from the abluminal
(brain) side and increase expression of adhesion mole-
cules on the luminal side [23], leading to enhanced
leukocyte engagement of the brain endothelium and
subsequent migration across the blood-brain barrier
(BBB) into the neuropil, further aggravating neuroin-
flammation [24]. In systemic inflammation (e.g., sepsis)
[25], there is an enhanced adhesion of leukocytes in dif-
ferent organs (including CNS) as well as cytokine pro-
duction that result in increased in BBB permeability.
During stroke, in response tissue injury/local cytokine/
chemokine production, neutrophils infiltrate ischemic
brain (in 30 min to a few hours), while monocytes/mac-
rophages migrate within a day or two, and T cells follow
on day 3 to 7 after an ischemic event [26, 27]. Lympho-
cyte/monocyte infiltration into the CNS is a signature
event in multiple sclerosis (MS), an inflammatory condi-
tion of the CNS. It remains enigmatic whether BBB dys-
function leads to immune cell infiltration or it is the
result of perivascular leukocyte accumulation, but
leukocyte migration definitely modifies BBB permeabil-
ity. Leukocytes in MS express inflammatory cytokines,
reactive oxygen species (ROS), and enzymes that can
augment their egress into the CNS by influencing BBB
function, either directly or indirectly [28, 29]. This
process is accompanied by BBB injury and increased
permeability to blood components toxic to neurons [30].
Therefore, approaches diminishing leukocyte interac-
tions with brain endothelial cells may prevent BBB dam-
age and attenuate neuroinflammation, resulting in
neuroprotection [31]. Inhibiting leukocyte migration
during the first stages of inflammation (in sepsis, MS, or
ischemia/reperfusion) may have positive effects by redu-
cing tissue injury, but on the other hand, prolonged in-
hibition might have negative effects in terms of
uncontrolled infections or prevention of immune cells
from initiation of regenerative activities, since inflamma-
tion is a vital part of the physiological reaction towards
tissue repair and plasticity [32–34]. It is essential to look
for anti-inflammatory treatments and to study their
mechanisms of action to be able to fine tune therapeutic
approaches.
Our prior work revealed that PARP inhibition in pri-
mary human brain microvascular endothelial cells
(BMVEC) decreased monocyte adhesion and migration
across BMVEC monolayers and attenuated expression of
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adhesion molecules. PARP suppression in BMVEC atten-
uated activity of small GTPases, dampened expression
and secretion of pro-inflammatory factors [35]. Utilizing
an in vivo aseptic meningitis/encephalitis model, we
demonstrated diminished adhesion and migration of leu-
kocytes across the BBB, confirming our in vitro
observations.
While we could selectively inhibit PARP in vitro in
BMVEC, it was impossible to distinguish whether de-
creased adhesion/migration in vivo resulted from PARP
inhibition in endothelium or from PARP suppression in
leukocytes as well. To challenge this issue, we used
adoptive transfer of leukocytes and intravital videomi-
croscopy (IVM) and found that leukocytes from PARP1
−/− mice (PARPko) displayed reduced adhesion and mi-
gration across cortical vessel endothelium vs. their wild-
type PARP1+/+ (WT) counterparts. To address putative
anti-inflammatory effects of PARP inhibition in leuko-
cytes, we pretreated human monocytes with PARPi and
showed their decreased adhesion/migration across BBB
models, paralleling attenuation of active integrin expres-
sion, cytoskeletal alterations, and GTPase activity. Gen-
etic or chemical inhibition of PARP in vivo prevented
their migration across the BBB and diminished barrier
permeability.
Methods
Reagents and cell culture
The selective PARPi used were 5-aminoisoquinolinone
(AIQ; Enzo Life Sciences, Farmingdale, NY); olaparib and
talazoparib (Selleck Chemicals, Houston, TX), 5′-deoxy-
5′-[4-[2-[(2, 3-dihydro-1-oxo-1H-isoindol-4-yl) amino]-2-
oxoethyl]-1-piperazinyl]-5′-oxoadenosine dihydrochloride
(EB47; Tocris Bioscience, Minneapolis, MN). The RhoA
inhibitor, CT04, and RhoA/Rac1 activator, CN04, were
from Cytoskeleton (Denver, CO). The Rac1 inhibitor,
NSC23766, was from EMD Millipore (Billerica, MA).
Lipopolysaccharide (LPS) from Escherichia coli 0111:B4
and Rhodamine 6G were from Sigma-Aldrich (St. Louis,
MO). Recombinant human tumor necrosis factor-α
(TNFα) and human monocyte chemotactic protein type-1
(MCP1/CCL2) were from R&D Systems (Minneapolis,
MN). Phorbol 12-myristate 13-acetate (PMA) was from
Cayman Chemical (Ann Arbor, MI).
Primary human monocytes from HIV-1/hepatitis B
seronegative donors were obtained from the University
of Nebraska Medical Center [36]. Primary brain micro-
vascular endothelial cells (BMVEC) were provided by
Dr. M. Witte (University of Arizona, Tucson, AZ), iso-
lated from the temporal cortex obtained during surgi-
cal removal of eleptogenic foci in adult patients [37]
and maintained in culture as described [9]. Cell cul-
ture reagents were from Life Technologies (Carlsbad,
CA).
Monocytes were pretreated with PARPi (AIQ 1 μM,
olaparib, EB47, 10 μM; talazoparib, 10, 25, or 10 nM)
[35, 38, 39] or RhoA/Rac1 activator/inhibitor (CN04,
1 μg/ml; CT04, 1 μg/ml; NSC23766, 75 μmol/l) for
30 min unless otherwise noted and did not affect cell
viability [39]. Dose-response results are shown in
Additional file 1: Figure S1. In all experiments, the desig-
nation non-treated (NT) indicates that medium only was
added to the cells.
Animals
C57BL/6 mice (8-week-old male) were from the Jackson
Laboratory (Bar Harbor, MI). PARPko mice (PARP1−/−)
were generated on C57BL/6J background [40] provided
by Dr. P. Pacher (NIAAA). To achieve statistical signifi-
cance in each experiment, mice were divided into groups
of four to six animals (exact numbers for each experi-
ment are indicated in figure legends).
All in vivo experiments were approved by the Temple
University Institutional Animal Care and Use Committee
in accordance with guidelines based on the National Insti-
tutes of Health (NIH) guide for care and use of laboratory
animals and ARRIVE (Animal Research: Reporting In
Vivo Experiments) guidelines (www.nc3rs.org.uk/arrive-
guidelines).
IVM and ex vivo treatment and labeling of leukocytes
Prior to IVM, mice underwent craniotomy and cranial
window implantation as described [41]. Prior to IVM,
mice were treated with LPS (6 mg/kg) i.v. or TNFα
(0.5 μg/mouse) by IC injection [9, 35, 42, 43]. Two hours
post-injection of TNFα, leukocytes were labeled in vivo
with Vybrant® DiI Cell-Labeling Solution (DiI) (Life
Technologies, Carlsbad, CA) introduced i.v. Leukocyte
adhesion was detected in cerebral vessels through the
cranial window using a SteREO Discovery V20 epifluor-
escence microscope (Carl Zeiss Microimaging Inc.,
Thornwood, NY) equipped with a AxioCam MR digital
camera as previously described [35, 44]. A 30-s video
(time-series image set between 16 and 20 frames/s) was
captured using the digital high-speed recorder. Adherent
leukocytes were defined as the number of leukocytes
firmly attached to the endothelium that did not change
location during the observation period, scored as the
number of cells per mm2 of the vascular surface area,
calculated from the diameter and length of the vessel
segment under observation. Imaris 8.3 software (Bitplane
AG, Zurich, Switzerland) was used to count adherent
leukocytes. Transmigrated leukocytes were enumerated
24 h later in an area covering a distance of 100 μm from
the pial and parenchymal vessel wall by epifluorescent
IVM. The number of extravasated leukocytes was
counted and normalized to area, using ImageJ software
(National Institutes of Health, Bethesda, MD) [35].
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Leukocytes were isolated from five donor mice PBMC
with red blood cell lysis buffer (eBioscience, Inc., San
Diego, CA). Leukocytes (2 × 106) were ex vivo treated
with PARPi for 30 min, washed with PBS, and labeled
with calcein-AM (1 μM, Life Technologies) as described
[9]. Concomitantly, recipient mice were treated with LPS
or TNFα as described above for 4 h, and mice were
anesthetized, injected intra-orbitally with Rhodamine 6G
to label autologous leukocytes, imaged by IVM, and then
injected with calcein-AM-labeled leukocytes. Leukocytes
were visualized by fluorescent light (495 or 601 nm exci-
tation for calcein-AM or Rhodamine 6G, respectively).
Ex vivo treatment of leukocytes did not change the
population profile (Additional file 1: Figure S2B).
In vivo permeability assay
Changes in BBB permeability were assessed using the
fluorescent tracer, sodium-fluorescein (Na-F) as de-
scribed [35, 41, 43]. Briefly, to prevent blood clotting in
the vessels, animals were injected i.p. with heparin
(20 U) followed i.v injection of 50 μl of 2 % Na-F in PBS.
The tracer was allowed to circulate for 30 min. The mice
were anesthetized and then transcardially perfused with
PBS until colorless perfusion was visualized. The animals
were then decapitated and the brains were quickly iso-
lated. After removal of the meninges, cerebellum, and
brain stem, the tissue was weighed and homogenized in
10 times volume of 50 % trichloroacetic acid. The hom-
ogenate was centrifuged for 10 min at 13,000×g, and the
supernatant was neutralized with 5 M NaOH (1:0.8).
The amount of Na-F was measured using a Synergy 2
plate reader (BioTek, Winooski, VT). Fluorescent dye
content was calculated using external standards; data are
expressed as amount of tracer per milligrams of tissue.
PARP activity assay
To measure PARP activity, leukocytes were treated with/
out PARPi for 30 min and then lysed and subjected to
ELISA according to manufacturer’s instructions (Trevigen,
Gaithersburg, MD).
Conformational changes of VLA-4 and LFA-1 integrins
To assess VLA-4 conformational status in monocytes, the
VLA-4-specific ligand, l-leucyl-l-aspartyl-l-valyl-l-prolyl-l-
alanyl-l-alanyl-l-lysine (LDV) (Tocris), was used. The acti-
vated conformation of VLA-4 was measured by flow cy-
tometry (FACS) using HUTS21 Ab as described [8]. To
assess LFA-1 conformational status, monocytes (0.5 × 106
cells/ml in RPMI medium/1 % FBS) were first treated
with/out inhibitors and then stimulated with PMA
(100 ng/ml) for 1 h. To prevent RhoA or Rac1 GTPase ac-
tivity, cells were pretreated with specific inhibitors, 1 μg/
ml CT04 (Cytoskeleton Inc.) or 75 μM NSC23766 (EMD
Millipore, Billerica, MA), respectively. Monocytes were
placed on ice and fixed with 4 % formaldehyde. Activated
LFA-1 conformation was detected by FACS with MEM-
148 Ab. Data were acquired with a FACS BD Canto II
flow cytometer (BD Biosciences, San Jose, CA) and ana-
lyzed with FlowJo software (Tree Star, Inc., Ashland, OR).
Data were collected from at least 10,000 events for each
experimental condition and repeated with monocytes
from three different donors. Quantitation of integrin con-
formational activation was performed, where the mean
fluorescence intensity (MFI) of activated non-treated cells
was assigned a value of 100 and the value of 0 was
assigned to the MFI of cell autofluorescence.
RhoA and Rac1 guanosine triphosphatase (GTPase)
activity assay
RhoA and Rac1 GTPase activities were measured by G-
LISA RhoA and Rac1 activation assay kits (Cytoskeleton
Inc., Denver, CO) in cell lysates prepared from mono-
cytes (with/out PARPi) after stimulation with MCP-1
(30 ng/ml) or PMA (100 ng/ml) for 1 h. To inhibit RhoA
or Rac1 GTPase activity, cells were pretreated with spe-
cific inhibitors, 1 μg/ml CT04 (Cytoskeleton Inc.) or
75 μM NSC23766 (EMD Millipore, Billerica, MA), re-
spectively. Monocytes stimulated with CN04 (Cytoskel-
eton Inc.) served as a positive control for Rho activity.
Quantification of F-actin and G-actin
Monocytes were treated with PARPi or RhoA/Rac1 in-
hibitors and stimulated by MCP-1 as described above,
washed with ice-cold PBS, and fixed with 4 % formalde-
hyde. Filamentous actin (F-actin) and globular actin (G-
actin) were stained by Acti-stain™ 488 phalloidin (Cyto-
skeleton) and DNase 1-Alexa 591 (Life Technologies),
respectively. Data were collected from at least 20,000
events for each sample by a BD FACS Influx and ana-
lyzed as described above. The F/G actin ratio was calcu-
lated by dividing the mean fluorescent intensity (MFI) of
F-actin by the MFI of G-actin.
Monocyte adhesion assay
BMVEC monolayers were treated overnight with TNFα
(20 ng/ml). Monocytes were treated overnight with/out
PARPi and washed prior to calcein-AM labeling. Fluores-
cence of adherent monocytes was measured using a Syn-
ergy 2 plate reader (BioTek, Winooski, VT) as described
[8]. Results are presented as the mean ± SEM fold adhe-
sion (number of adherent monocytes for each experimen-
tal condition divided by the basal adhesion of the
untreated control), which was assigned a value of 1 (7600
relative fluorescent units).
Transendothelial migration assay
Monocytes were treated with PARPi, labeled as de-
scribed above, and washed before addition to BMVEC.
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FluoroBlok (BD Bioscience, Bedford, MA) cell culture
inserts, intended to block the transmission of fluores-
cent light between 490 and 700 nm, were used to
permit continuous detection of fluorescently labeled
monocytes migrating across endothelial monolayers.
BMVEC were seeded on collagen type I coated 3-μm
pore 24-well tissue culture FluoroBlok inserts at a
density of 2.5 × 104 cells per insert. Confluent mono-
layers were then exposed to TNFα (20 ng/ml) for
24 h to activate the BMVEC. After activation,
BMVEC were rinsed with fresh medium and the
medium was replaced. For migration assays, calcein-
AM-labeled monocytes were added to the upper
chamber of the tissue culture insert system, while the
chemoattractant, CCL2/MCP-1 (30 ng/ml), was added
to the lower chamber to stimulate migration. Chemo-
taxis towards MCP-1 was allowed for 2 h as de-
scribed [8]. The number of migrated monocytes was
determined using ImageJ software (NIH) and pre-
sented as fold difference in migration from triplicate
determinations, calculated from the number of mi-
grated monocytes for each experimental condition di-
vided by the number of migrated monocytes in the
untreated, no chemoattractant control (assigned a
value of 1, equivalent to 37 migrated cells).
Transendothelial electrical resistance (TEER)
To determine the integrity of brain endothelial mono-
layers after engagement with monocytes, TEER was
measured using the 1600R ECIS system (Applied Bio-
physics, Troy, NY). Using the free ions in the culture
media, the instrument generates an AC current flow
between the electrode and counter electrode located
in specialized tissue culture arrays and measures the
change in impedance. The ECIS system provides real-
time complex impedance, providing readouts for im-
pedance, resistance, and capacitance. In brief, BMVEC
were plated on collagen-coated electrode arrays
(96W20idf ) and maintained until a monolayer formed
with a TEER of 800–1500 Ω. Monocytes were treated
with/out PARPi overnight, rinsed prior to the addition
of monocytes (1 × 105 cells/well) to the BMVEC. Mea-
surements were taken every 30 min at 4000 Hz as de-
scribed [39, 43]. The results are presented as the
percent change from baseline TEER from at least two
independent experiments (expressed as average ±
SEM) consisting of four to six replicates each (100 %
equals a resistance of 644Ω).
Statistical analysis
The results are expressed as the mean ± SEM of experi-
ments conducted multiple times. Multiple group com-
parisons were performed by one-way analysis of variance
with Dunnet’s post hoc tests. Statistical analyses were
performed utilizing Prism v5 software (GraphPad Soft-
ware Inc., La Jolla, CA). Differences were considered sig-
nificant at P values <0.05.
Fig. 1 PARP deficiency diminishes leukocyte adhesion to and migration across the BBB and reduces BBB permeability. Representative images
from videos of leukocytes labeled with Rhodamine 6G for adhesion (a) and migration (b). Measurement of labeled leukocytes after their adhesion
to (c) or migration (d) across the endothelium. e Measurement of BBB permeability in vivo by sodium-fluorescein accumulation in the brain in
the presence or absence of LPS. Results are shown as mean adhesion or migration ± SEM (four animals per treatment group). **P < 0.01 indicates
significance vs. TNFα or LPS-treated animals. Scale bar = 100 μm is shown in one micrograph, but it is valid for all micrographs shown
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Results
PARPko mice exhibit decreased leukocyte adhesion to
and migration across the brain endothelium in vivo and
attenuated enhanced BBB permeability in TNFα-induced
encephalitis
Recently, we demonstrated that PARP inhibition in
BMVEC lessened monocyte adhesion and migration
across BMVEC monolayers and attenuated expression of
adhesion molecules [35]. To further assess effects of
PARP inhibition on leukocyte adhesion/migration, we
used IVM in PARPko and WT mice, utilizing systemic
LPS-induced inflammation [35] and TNFα-mediated en-
cephalitis (by IC injection). In WT mice, LPS and TNFα
treatment resulted in 52- and 42-fold increases in
leukocyte firm adhesion, respectively, whereas PARPko
mice showed decreased level of leukocyte adhesion with
both LPS (74 %) and TNFα (25 %) (Fig. 1a, c).
IVM showed increased leukocyte migration across the
brain endothelium after IC TNFα administration by
14.5-fold vs. baseline in WT mice, while PARPko mice
displayed only a 2.6-fold increase vs. baseline (Fig. 1b,
d). Because leukocyte engagement of endothelium and
inflammation results in enhanced permeability of the
BBB, we determined the effect of PARP inhibition on
barrier permeability in a LPS-induced systemic inflam-
mation model. The amount of Na-F in the whole brain
was elevated 1.7-fold after LPS-treatment of WT mice
compared to untreated WT mice (Fig. 1e) whereas in
PARPko mice, Na-F accumulation was significantly de-
creased in untreated and LPS-treated PARPko animals
as compared to WT mice (Fig. 1e). These results further
indicate that suppression of PARP activity protects BBB
integrity.
Inhibition of PARP decreases leukocyte adhesion to the
brain endothelium in an adoptive transfer mouse model
of LPS-induced systemic inflammation
Our previous work utilizing systemic PARPi administra-
tion [35] or PARPko animals (Fig. 1) did not allow us to
determine whether the effects observed were due to
diminution of inflammatory responses in endothelial
cells or in leukocytes. Therefore, we evaluated the effect
Fig. 2 PARP inhibition decreases leukocyte adhesion in brain microvessels during systemic inflammation. a Representative images from videos of
leukocytes labeled with calcein-AM. b Measurements of leukocyte firm (not rolling) adhesion during a 30-s observation period (ex vivo treated,
calcein-AM-labeled leukocytes). Leukocytes were treated ex vivo with or without PARP inhibitors for 4 h. c Measurements of leukocyte firm (not
rolling) adhesion during a 30-s observation period (autologous, Rhodamine 6G-labeled leukocytes). Results are shown as mean adhesion ± SEM
(four to six animals per treatment group). ns indicates no significance, **P < 0.01, ***P < 0.001 indicates significance vs. NT. Scale bar = 100 μm is
shown in one micrograph, but it is valid for all micrographs shown
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of selective PARP inhibition in leukocytes on their adhe-
sion in vivo utilizing adoptive transfer. Leukocytes were
isolated from WT mice, treated ex vivo with/out PARPi,
labeled with calcein-AM, washed, injected into LPS-
treated WT mice, and monitored by IVM. Olaparib and
EB47 ex vivo treatment reduced PARP activity to levels
close to PARPko leukocytes, whereas AIQ reduced PARP
activity by 53 % (Additional file 1: Figure S2A). LPS
treatment increased leukocyte attachment (adhesion)
>40-fold to the brain endothelium, while leukocytes
ex vivo treated with PARPi displayed significantly de-
creased adhesion compared to untreated leukocytes
by 71–87 % (Fig. 2a, b). Mice injected with LPS
showed ~30-fold increase in firm adhesion of autolo-
gous (non-treated) leukocytes to the cortical endothe-
lium (Fig. 2c). These results demonstrate that PARPi
have potent in vivo anti-inflammatory properties in
leukocytes.
PARP inactivation in leukocytes attenuates adhesion to
the brain endothelium
Since administration of PARPi significantly reduced
leukocyte adhesion to cortical vessels, we hypothesized
that PARP inhibition would affect the ability of leuko-
cytes to adhere to cortical vessels. We performed adop-
tive transfer where ex vivo-labeled leukocytes, isolated
from PARPko animals, were i.v.-injected into recipient
WT animals and vice versa, utilizing a LPS-induced sys-
temic encephalitis model. PARPko leukocytes transferred
to WT mice exhibited 36 % decreased adhesion com-
pared to WT PARP-expressing leukocytes injected to
WT mice (Fig. 3a, b). When PARPko leukocytes were
Fig. 3 PARP ko mice show diminution of leukocyte adhesion to the brain endothelium in vivo. a Representative images from videos of leukocytes
labeled with calcein-AM (upper panels) or Rhodamine 6G (lower panels). b Measurement of labeled leukocytes under firm (not rolling) adhesion in WT
or PARP ko mice during a 30-s observation period (ex vivo treated, calcein-AM-labeled leukocytes). c Measurements of leukocyte firm (not rolling)
adhesion during a 30-s observation period (autologous, Rhodamine-labeled leukocytes). Results are shown as mean adhesion ± SEM (four animals per
treatment group). ns indicates no significance, **P < 0.01, ***P < 0.001, ****P < 0.0001 indicates significance vs. LPS treated. Scale bar = 100 μm is shown
in one micrograph, but it is valid for all micrographs shown
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transferred to PARPko mice, leukocytes showed even
further decrease in adhesion. Whereas the cells from the
PARPko mice were able to adhere much better in the
WT mice compared to the PARPko mice mimicking re-
sults in Fig. 1c, and leukocyte adhesion in the PARPko
animals was reduced too. Adhesion of autologous leuko-
cytes did not change, regardless of the type of trans-
ferred leukocytes (Fig. 3c). These results support our
idea that inhibition of PARP in leukocytes affects their
capability to adhere to endothelium.
Fig. 4 PARP inhibition prevents adhesion to and migration of monocytes across BMVEC monolayers preserving the barrier. Primary human
monocytes were treated for 24 h with PARPi (AIQ, olaparib, EB47, talazoparib), calcein-labeled, washed, and then added to BMVEC monolayers
(untreated or treated for 24 h with TNFα). Treatments were removed prior to the addition of monocytes. Adhesion to (a) and migration of (b)
monocytes across blood-brain barrier models were measured and are presented as fold difference compared to TNFα-only control (mean ± SEM)
for each treatment from at least quadruplicate determinations, which was assigned a value of 1 (7600 relative fluorescent units for adhesion or
equivalent to 37 migrated cells). *P < 0.05, **P < 0.01 indicate significance vs. non-treated. TEER, an indicator of barrier integrity, was continuously
measured in BMVEC monolayers treated with or without TNFα following the addition of primary human monocytes that had been treated with
PARPi. c Dose-dependent treatment of monocytes with talazoparib at 10, 25, or 100 nM. d Treatment of monocytes with AIQ, olaparib, EB47 at
10 μM, and talazoparib at 100 nM; the percent change in TEER at 3, 10, and 17 h is shown. Data are presented as the percent change from
baseline TEER (mean ± SEM) for at least six replicates (100 % equals a resistance of 644Ω). ***P < 0.005 indicate significance vs. non-PARPi treated
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Fig. 5 (See legend on next page.)
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PARP suppression in monocytes decreases adhesion to
BMVEC monolayers and transendothelial migration
We determined whether our in vivo observations could
be confirmed in an in vitro BBB system utilizing primary
human monocytes and human BMVEC. Monocytes were
treated with PARPi, washed and added to TNFα-
stimulated BMVEC. Monocyte adhesion to BMVEC was
increased nearly fourfold following TNFα treatment and
was significantly inhibited by the PARPi, AIQ, Olaparib,
and EB47 (by 55, 91, and 47 %, respectively) (Fig. 4a). In
dose-response experiments, talazoparib reached a signifi-
cant (86 %) decrease in adhesion at 100 nM. We next
determined if PARP inhibition in monocytes would
affect their transendothelial migration through BMVEC
monolayers. Monocytes were treated with PARPi; after
treatments were removed, MCP-1 was added to the
lower chamber of BBB constructs, which resulted in a
twofold increase in monocyte migration towards the
chemoattractant. Monocyte migration was completely
abolished by PARPi, olaparib, EB47, and talazoparib
(Fig. 4b). These in vitro protective effects observed with
PARPi on monocyte/endothelial interactions in adhe-
sion/migration assays are consistent with our in vivo
results.
PARP inhibition prevents monocyte-mediated disruption
of the BBB
To understand if PARP inhibition in monocytes could
diminish their activation, lessen BMVEC engagement,
and preserve barrier integrity in brain endothelial
cells in vitro, we used TEER to assess barrier tight-
ness in BMVEC monolayers. BMVEC demonstrated
the expected steady state barrier formation, but
monocyte addition resulted in a rapid diminution
(15–20 %) in resistance (mimicking BBB injury in
vivo) that was maintained for the experiment’s dur-
ation. Dose-response monocyte exposure to talazo-
parib, significantly attenuated monocyte engagement-
induced drop in resistance, enhancing TEER by 7–10,
10–13, and 17–27 % (Fig. 4c). AIQ, olaparib, and
EB47 also prevented barrier injury, as demonstrated
by 3–10 % increases in TEER (Fig. 4d). Taken to-
gether, these results demonstrate that PARP inhibition
in monocytes decreases their engagement with endo-
thelium and protects barrier integrity in vitro.
Inhibition of PARP prevents conformational activation of
VLA-4 and LFA-1 integrins in monocytes
The adhesion of monocytes to activated endothelial cells
is governed by conformational changes in the integrins,
including VLA-4 and LFA-1 [8]. We evaluated expres-
sion of active forms of VLA-4 following stimulation with
LDV (a peptide mimicking activation during exposure to
the adhesion molecule, VCAM-1, and fibronectin),
which resulted in a change in integrin β1 conformation
from inactive (closed/non-adherent) to active (open/ad-
herent) form. PARPi treatment of monocytes drastically
decreased LDV-induced expression of active integrin β1,
as did treatment with Rac1 inhibitor, NSC23766 (>90 %)
(Fig. 5). The RhoA inhibitor, CT04, decreased this to a
lesser degree (40 %).
Activation of primary human monocytes by PMA
resulted in a significant twofold upregulation of the
active form of LFA-1, while exposure to olaparib,
EB47, or talazoparib resulted in a significant decline
of activated LFA-1 compared to untreated monocytes
(Fig. 6). Rac1 inhibitor treatment also significantly de-
creased LFA-1 activation (P < 0.05). However, RhoA
inhibitor treatment reduced LFA-1 activation with
lesser extent (P < 0.5).
PARP inactivation in monocytes affects actin cytoskeleton
We next measured PARP inhibition effects on actin
cytoskeleton rearrangements in monocytes. MCP-1-
stimulation of monocytes resulted in a 5.6-fold in-
crease in F/G actin ratio (Fig. 7a). PARPi treatment
of monocytes resulted in a 28 % decrease in F/G ac-
tion ratio. Specific RhoA and Rac1 inhibitors also
decreased F/G actin ratio, indicating that PARP in-
hibition affects the actin cytoskeleton via RhoA and
Rac1 inhibition. We next evaluated the activation of
the small GTPases, RhoA, and Rac1, in monocytes,
in view of their role in the actin cytoskeleton
rearrangements during their adhesion and migration.
MCP-1-stimulated monocytes showed increased
RhoA by 1.6 (Fig. 7b). MCP-1- or PMA-stimulated
monocytes exhibited amplified Rac1 activation by 4-
and 5.9-fold, respectively (Fig. 7c). PARPi, olaparib,
and talazoparib significantly reduced activation of
both Rho GTPases.
(See figure on previous page.)
Fig. 5 PARP inhibition prevents conformational activation of VLA-4 (integrin β1) in monocytes. Monocytes were treated with PARPi (AIQ or EB47)
or RhoA or Rac1 GTPase inhibitor (CT04 or NSC23766). The expression of total VLA-4 (CD29) was unaffected by treatment with PARP inhibitors.
a The active form of VLA-4 was detected using HUTS21, a conformation-specific antibody. Integrin conformation in monocytes changes from a
closed (inactive) to an open (active) form after LDV stimulation. Total amount of integrin β1 (CD29) is shown on the x-axis. b Quantitation of
integrin β1 conformational activation, expressed as the percent of monocytes containing the activated integrin conformation (as shown in the
right upper quadrant of each graph in panel a). Results are presented as the mean ± SEM (**P < 0.01, ****P < 0.005 vs. untreated control) from
three independent experiments
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Fig. 6 (See legend on next page.)
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Discussion
Leukocyte trafficking from blood into tissues is a vital
response to injury and involves multiple steps mediated
by adhesion molecules and chemoattractants. Inflamma-
tion and its associated infiltration of various leukocyte
types, as well as leukocyte-endothelium interaction, play
a significant role in numerous CNS diseases; therefore,
the molecular mechanisms controlling leukocyte migra-
tion are potential therapeutic targets. Inflammatory and
immune cells play complex roles after ischemic stroke,
MS, encephalitis, and meningitis [10, 19, 45–48]. Actin
cytoskeleton machinery, integrins, and their conform-
ational changes are key elements in the ability of
leukocyte subsets to roll on endothelial cells, arrest and
firmly adhere, and transmigrate across the BBB, leading
to its dysfunction and neuroinflammation resulting in
neuronal dysfunction. Lessening leukocyte adhesion and
migration might serve as an ultimate tool in weakening
of inflammatory events in the brain.
PARP suppression has been shown to diminish edema,
preserve the tight junction protein, occludin, and de-
crease expression of the adhesion molecule, ICAM-1, in
animal models of stroke, traumatic brain injury, menin-
gitis, and MS [45, 49–51], reducing leukocyte infiltration
and brain inflammation [49, 52]. Application of PARPi
has been previously shown to reduce leukocyte adhesion
[49, 52]. However, these studies did not address whether
the effects of PARP inactivation apply to immune cells,
to endothelium or to both. Recently, we showed that
PARP inhibition caused a significant reduction in
leukocyte adhesion/migration in a novel in vivo model
of localized neuroinflammation as well as in systemic in-
flammation, thereby preserving BBB integrity [35]. Add-
itionally, inhibition of PARP in BMVEC resulted in
attenuation of expression of adhesion molecules, such
VCAM-1 and ICAM-1, and diminished secretion of pro-
inflammatory cytokines [35].
In the present study, we used IVM to demonstrate that
PARP inactivation in leukocytes drastically attenuated
leukocyte adhesion/migration to and across cortical ves-
sels in two in vivo models, LPS-induced systemic inflam-
mation, and TNFα-induced localized encephalitis (Fig. 2),
whereas autologous leukocytes displayed regular adhesion.
PARPko animals exhibited attenuated inflammation-
caused permeability vs. WT mice (Fig. 1c). PARP absence
resulted in a decreased number of adherent leukocytes
when injected into WT mice or an enhanced number of
adherent leukocytes when WT leukocytes were intro-
duced into PARPko mice (Fig. 3). Interestingly, the cells
from the PARPko mice were able to adhere much better
in the WT mice vs. the PARPko mirroring results in
Fig. 1c, whereas leukocyte adhesion in the PARPko ani-
mals was reduced too, not only the leukocyte adhesion
machinery was affected in these animals but also the BBB
was less impaired [35]. Our in vivo results were repro-
duced in vitro where PARPi-treated monocytes showed
substantially reduced adhesion to and migration across
BMVEC monolayers (Fig. 4). The present study deter-
mined that inactivation of PARP in primary human mono-
cytes tempered barrier dysfunction (denoted by a TEER
reduction) (Fig. 4), with diminished monocyte engagement
of the brain endothelium (adhesion/migration).
We have explored the idea that PARP inactivation re-
sults in conformational changes of active integrin and/or
total integrin expression. Inactivation of PARP and Rac1
inhibition attenuated active integrin β1 expression
(Fig. 5), while expression of total VLA-4 was unchanged,
demonstrating the importance of VLA-4 conformation.
Conformational activation of integrin apparently exposes
the VCAM-1 binding site [53], facilitating both tethering
and rolling [54]. It has been shown that memory T cells,
constitutively expressing activation/ligand-induced epi-
topes on β1 integrins, exhibit significantly higher rates
of attachment and accumulation on VCAM-1 expressing
cells compared to other T cell subsets without active epi-
tope expression [9, 55]. Previously, we [8, 9] and others
[56] have shown a link between conformational VLA-4
activation and Rac1 pathways (inhibition of GSK3β or
Rac-1, or CB2 activation), leading to lessened expression
of the active VLA-4 form resulted in attenuated mono-
cyte adhesion/migration in BMVEC [8, 9].
LFA-1 inside-out activation was stimulated by PMA in
primary monocytes, and Rac1 inhibition or PARP inacti-
vation decreased LFA-1 conformational change, whereas
RhoA inhibition had no effect (Fig. 6). It has been shown
that Rac1 plays an important role in LFA-1 activation in
T cells [57]. Mutations of the LFA-1 β2-subunit pre-
vented LFA-1 surface expression [58], resulting in type I
leukocyte adhesion deficiency, which is induced by small
Rho GTPase signaling [59].
(See figure on previous page.)
Fig. 6 PARP suppression diminishes conformational activation of LFA-1 (integrin β2) in monocytes. Monocytes were treated with PARPi (olaparib,
EB37, or talazoparib) or RhoA and Rac1 GTPase inhibitor (CT04 or NSC23766). Expression of total LFA-1 (CD18) was not affected by treatment with
PARPi. The activated form of LFA-1 was detected using MEM-148, a conformation-specific antibody. PMA-stimulation of monocytes changes
integrin conformation from a closed (inactive) to an open (active) form (a). The total amount of integrin β2 (CD18) is shown on the x-axis. b
Quantitation of integrin β2 conformational activation, expressed as the percent of monocytes containing the activated integrin conformation (as
shown in the right upper quadrant of each graph in panel a). Results are presented as the mean ± SEM (*P < 0.5, **P < 0.05 vs. untreated control)
from three independent experiments
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Small GTPases (Rho, Rac, and Cdc42) play a vital role
in transendothelial leukocyte migration, oxidative stress,
and inflammation by linking surface receptors and the
actin cytoskeleton [60, 61]. Rac1 and Cdc42 in
leukocytes control lamellipodia formation, cell polarity,
and direct migration, while RhoA controls leukocyte tail
retraction during transmigration [62]. Given outcomes
of functional assays, we measured RhoA and Rac1 acti-
vation after MCP-1 or PMA stimulation of monocytes
and showed a decrease in active GTPases after PARP in-
activation, resulting in diminution of actin cytoskeletal
rearrangements (Fig. 7), which play a central role in cell
migration [8, 63–65]. F-actin-rich lamellipodia formation
caused by stimulating actin filament disassembly near
the pointed ends supplies actin monomers for
polymerization [66]. MCP-1 stimulation resulted in
amplified actin rearrangements in monocytes (high F/G
actin ratio), whereas PARP inactivation substantially di-
minished F/G actin ratio (Fig. 7). RhoA and Rac1 inhibi-
tors exhibited analogous results, further signifying their
involvement in this process.
There is a good amount of literature suggesting that
PARP serves as a key component in nuclear factor kappa
B, NFkB, activation, and consequently to transcription
and expression of many inflammatory genes [35, 39, 67–
69]. In brain-resident microglia, TNFα activates PARP in
a DNA damage-independent manner, involving phos-
phatidyl choline-specific phospholipase and the MAPK
kinase, ERK [70].
Rho GTPases are known to participate in MAPK kin-
ase signaling activation [71]. In hepatocytes, MAPK kin-
ase downregulation significantly abrogated the Rho
pathway and cytoskeleton reorganization [72]. It is
widely accepted that there is a relationship between
PARP and MAPK, suggesting that they might stimulate
each other in a feedback cycle [73]. Both MAPK kinases
and Rho GTPases are involved in cytoskeleton rear-
rangements and cell migration [9, 71, 74]. Deeper under-
standing of these signal transduction interrelations may
contribute to the development of more fine-tuned anti-
inflammatory therapeutics.
Oxidative stress plays an important role in many
neuroinflammatory conditions [75, 76]. Prolonged oxi-
dative stress might lead to alterations in actin cyto-
skeleton in leukocytes [77]. In recent years, numerous
PARP functions have been discovered, involving the
regulation of oxidative stress and inflammation via
complex interlinked signaling networks [73, 78]. Free
radicals are potent activators of PARP; consequently,
augmented PARP activity is usually associated with
oxidative/nitrative stress [79]. Although the latest re-
ports have implicated a bidirectional relationship,
PARP inhibition itself is capable of reducing ROS for-
mation in various pathologies [51, 79, 80]. PARP acti-
vation affects the energy balance of cells by NAD+
depletion, thereby causing compromised glycolysis
and ATP depletion [78]. Functional behavior of im-
mune cells (macrophages) is intensely coordinated by
Fig. 7 PARP inhibition suppresses the activation of GTPases in
monocytes and decreases cytoskeletal changes. Monocytes were
pretreated with PARPi (olaparib or talazoparib) or RhoA or Rac1
inhibitor (CT04, NSC23766) before stimulation by MCP-1. a F/G
actin ratio in monocytes treated with PARP inhibitors or RhoA/Rac1
inhibitors. G-LISA was used to measure RhoA (b) and Rac1 GTPase
activity (c) in cell lysates prepared from the monocytes. The level of
RhoA or Rac1 activity in non-stimulated, non-treated cells was
assigned a value of 1. Results are shown as the mean ± SEM
(*P < 0.5, **P < 0.05 vs. untreated control) from three
independent experiments
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actin cytoskeleton rearrangements, a process in which
ATP and NAD+ also play an indispensable role [81].
In this report, we did not study PARP activation-
stimulated energy depletion and its effects on
leukocyte function. However, understanding the role
of PARP-stimulated NAD+ depletion and leukocyte
actin cytoskeleton machinery during inflammation is
required in the future. Two PARPi that were used in
this study, talazoparib and olaparib, are now in clin-
ical trials for treatment of several cancers (phase II
and III) [10], promising speedy translation in evolving
therapeutic route in various inflammatory diseases
[82]. While the anti-inflammatory effects of PARP in-
hibition are gaining momentum [83], exact mecha-
nisms are still largely unknown (especially in the
CNS).
The concept that BBB damage is tied to leukocyte
migration into the CNS is well accepted [28]. There-
fore, attenuated adhesion of inflammatory cells to the
brain endothelium via inhibition of PARP may prove
valuable in stroke, MS or infection-associated enceph-
alitis, and other inflammatory disorders. Particularly
for the field of stroke, the inflammatory response has
Janus-faced effects. Inflammation is known to have
deleterious effects [32, 84–86], but is also known to
initiate regenerative processes, leading to the perspec-
tive that inflammation is a necessary part of the
physiological reaction towards tissue repair and plasti-
city [32–34]. In this perspective, effects resulting in
BBB opening after an acute stimulus (during ische-
mia/reperfusion) and PARP inhibition might be very
valuable, but long-term effects of PARP inhibition
need to be investigated further before such an inter-
vention could be considered clearly beneficial. Here,
we have described previously unrecognized effects of
PARP inhibition on diminution of VLA-4 and LFA-1
activation, mitigation of actin cytoskeleton rearrange-
ments via small GTPases, and attenuation of
leukocyte adhesion and migration across the BBB. At-
tenuation of leukocyte invasion is associated with
minimized brain damage and might serve to translate
these experimental findings into clinical therapies.
Conclusions
Neuroinflammation is accompanied by leukocyte infil-
tration into the brain resulting in subsequent BBB
dysfunction and significantly contributing to morbid-
ity in ischemic stroke, multiple sclerosis, encephalitis,
and traumatic brain injury. Pathways that reduce the
inflammatory potential of leukocytes would prevent
such damage. Our results suggest PARP inhibition in
leukocytes as a novel approach to BBB protection in
the setting of endothelial dysfunction caused by
inflammation-induced leukocyte engagement.
Additional file
Additional file 1: Figure S1. PARPi decrease PARP activity in a dose-
dependent manner. PARP activity of primary monocytes treated with
different concentrations of PARPi AIQ (A) and olaparib (B). Results are
presented as the mean ± SEM (*P < 0.05, **P < 0.01 vs. untreated control)
from two independent experiments for at least three replicates. Figure
S2. PARP activity significantly diminished in ex vivo treated mouse
leukocytes. (A) PARP activity was measured in freshly isolated and ex vivo
PARPi-treated mouse leukocytes. Data are presented as mean ± SEM for
at least three replicates from three/four donor mice. ***P < 0.005 indicate
significance vs. non-treated. (B) Flow cytometry data presenting leukocyte
profile of isolated leukocytes with or without PARPi treatment.
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